- Home
- AWI vs LEGN Comparison
AWI vs LEGN Comparison
Compare AWI & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AWI
- LEGN
- Stock Information
- Founded
- AWI 1860
- LEGN 2014
- Country
- AWI United States
- LEGN United States
- Employees
- AWI N/A
- LEGN N/A
- Industry
- AWI Plastic Products
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- AWI Industrials
- LEGN Health Care
- Exchange
- AWI Nasdaq
- LEGN Nasdaq
- Market Cap
- AWI 6.7B
- LEGN 7.8B
- IPO Year
- AWI 2006
- LEGN 2020
- Fundamental
- Price
- AWI $142.76
- LEGN $34.08
- Analyst Decision
- AWI Buy
- LEGN Strong Buy
- Analyst Count
- AWI 6
- LEGN 13
- Target Price
- AWI $140.83
- LEGN $81.54
- AVG Volume (30 Days)
- AWI 197.7K
- LEGN 1.5M
- Earning Date
- AWI 02-18-2025
- LEGN 11-12-2024
- Dividend Yield
- AWI 0.86%
- LEGN N/A
- EPS Growth
- AWI 13.35
- LEGN N/A
- EPS
- AWI 5.66
- LEGN N/A
- Revenue
- AWI $1,390,300,000.00
- LEGN $520,183,000.00
- Revenue This Year
- AWI $11.49
- LEGN $120.77
- Revenue Next Year
- AWI $6.99
- LEGN $68.54
- P/E Ratio
- AWI $25.22
- LEGN N/A
- Revenue Growth
- AWI 7.99
- LEGN 122.96
- 52 Week Low
- AWI $95.24
- LEGN $32.50
- 52 Week High
- AWI $164.40
- LEGN $70.13
- Technical
- Relative Strength Index (RSI)
- AWI 30.06
- LEGN 31.74
- Support Level
- AWI $152.56
- LEGN $32.50
- Resistance Level
- AWI $152.56
- LEGN $35.08
- Average True Range (ATR)
- AWI 3.32
- LEGN 1.98
- MACD
- AWI -2.39
- LEGN -0.51
- Stochastic Oscillator
- AWI 11.46
- LEGN 13.10
About AWI Armstrong World Industries Inc
Armstrong World Industries Inc is engaged in the design, innovation and manufacture of ceiling and wall solutions in the Americas. The products include mineral fiber, fiberglass wool, metal, wood, wood fiber, glass-reinforced-gypsum and felt. The company also manufactures ceiling suspension system (grid) products through a joint venture with Worthington Industries, Inc. called Worthington Armstrong Venture (WAVE).
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.